Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 9, 2014, Pages 1294-1304

  Schmidt, Lars Henning ^a   Görlich, Dennis ^b   Spieker, Tilmann ^c   Rohde, Christian ^a   Schuler, Martin ^d,e   Mohr, Michael ^a   Humberg, Julia ^a   Sauer, Tim ^a   Thoenissen, Nils H ^a   Huge, Andreas ^b   Voss, Reinhard ^b   Marra, Alessandro ^f   Faldum, Andreas ^b   Müller Tidow, Carsten ^a   Berdel, Wolfgang E ^a   Wiewrodt, Rainer ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f Klinikum St Georg   (Germany)

Author keywords

Apoptosis; MALAT 1; NSCLC; Overall survival

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; BARRIER TO AUTOINTEGRATION FACTOR; CASPASE 3; K RAS PROTEIN; LONG UNTRANSLATED RNA; MALAT 1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEAR RECEPTOR NUR77; PHAPI PROTEIN; PHOSPHOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; MALAT1 LONG NON-CODING RNA, HUMAN; RNA; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER HISTOLOGY; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MUTATIONAL ANALYSIS; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SURVIVAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS;

AGED; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, LONG NONCODING; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 84906306665     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000243     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Brambilla E, Gazdar A. Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J 2009;33:1485-1497.
3. Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59:790-800.
4. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984;226:1097-1099.
5. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-1443.
6. Boise LH, González-García M, Postema CE, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
7. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899-1911.
8. Kelekar A, Thompson CB. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 1998;8:324-330.
9. Muchmore SW, Sattler M, Liang H, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996;381:335-341.
10. Hsu YT, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci U S A 1997;94:3668-3672.
11. Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta 2004;1644:107-113.
12. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002;100:194-199.
13. Zhang H, Guttikonda S, Roberts L, et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 2011;30:1963-1968.
14. Bai J, Brody JR, Kadkol SS, Pasternack GR. Tumor suppression and potentiation by manipulation of pp32 expression. Oncogene 2001;20:2153-2160.
15. Brody JR, Kadkol SS, Hauer MC, Rajaii F, Lee J, Pasternack GR. pp32 reduction induces differentiation of TSU-Pr1 cells. Am J Pathol 2004;164:273-283.
16. Hoffarth S, Zitzer A, Wiewrodt R, et al. pp32/PHAPI determines the apoptosis response of non-small-cell lung cancer. Cell Death Differ 2008;15:161-170.
17. Cox G, Louise Jones J, Andi A, Abrams KR, O'Byrne KJ. Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer. Lung Cancer 2001;34:417-426.
18. Fokkema E, Timens W, de Vries EG, et al. Expression and prognostic implications of apoptosis-related proteins in locally unresectable nonsmall cell lung cancers. Lung Cancer 2006;52:241-247.
19. Fontanini G, Boldrini L, Vignati S, et al. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer 1998;34:718-723.
20. Higashiyama M, Doi O, Kodama K, Yokouchi H, Nakamori S, Tateishi R. bcl-2 oncoprotein in surgically resected non-small cell lung cancer: possibly favorable prognostic factor in association with low incidence of distant metastasis. J Surg Oncol 1997;64:48-54.
21. Jeong SH, Jung JH, Han JH, et al. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Lung Cancer 2010; 68:288-294.
22. Laudanski J, Chyczewski L, Niklińska WE, et al. Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival. Neoplasma 1999;46:25-30.
23. Ohsaki Y, Toyoshima E, Fujiuchi S, et al. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res 1996;2:915-920.
24. Renouf DJ, Wood-Baker R, Ionescu DN, et al. BCL-2 expression is prognostic for improved survival in non-small cell lung cancer. J Thorac Oncol 2009;4:486-491.
25. Silvestrini R, Costa A, Lequaglie C, et al. Bcl-2 protein and prognosis in patients with potentially curable non-small-cell lung cancer. Virchows Arch 1998;432:441-444.
26. Yoo J, Jung JH, Lee MA, et al. Immunohistochemical analysis of nonsmall cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci 2007;22:318-325.
27. Groeger AM, Esposito V, De Luca A, et al. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology 2004;44:54-63.
28. Kim YC, Park KO, Kern JA, et al. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998;22:181-190.
29. Poleri C, Morero JL, Nieva B, et al. Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis. Chest 2003;123:1858-1867.
30. Berrieman HK, Smith L, O'Kane SL, Campbell A, Lind MJ, Cawkwell L. The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes. Cancer 2005;103:1415-1419.
31. Karczmarek-Borowska B, Filip A, Wojcierowski J, et al. Estimation of prognostic value of Bcl-xL gene expression in non-small cell lung cancer. Lung Cancer 2006;51:61-69.
32. Sánchez-Ceja SG, Reyes-Maldonado E, Vázquez- Manríquez ME, López- Luna JJ, Belmont A, Gutiérrez- Castellanos S. Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-smallcell lung carcinoma. Lung Cancer 2006;54:163-168.
33. Guo F, Li Y, Liu Y, Wang J, Li Y, Li G. Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. Acta Biochim Biophys Sin (Shanghai) 2010;42:224-229.
34. Schmidt LH, Spieker T, Koschmieder S, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol 2011;6:1984-1992.
35. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
36. Travis WD, Colby TV, Corrin B, et al. Histological Typing of Lung and Pleural Tumours. 3 ed. Berlin, Heidelberg, New York: Springer Verlag Berlin Heidelberg; 1999:1-70.
37. Schmidt LH, Biesterfeld S, Kümmel A, et al. Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue. Anticancer Res 2009;29:201-209.
38. Friess H, Lu Z, Graber HU, et al. bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 1998;43:414-421.
39. Fu YC, Chi CS, Yin SC, Hwang B, Chiu YT, Hsu SL. Norepinephrine induces apoptosis in neonatal rat endothelial cells via down-regulation of Bcl-2 and activation of beta-adrenergic and caspase-2 pathways. Cardiovasc Res 2004;61:143-151.
40. Ghosh A, Sarkar SN, Rowe TM, Sen GC. A specific isozyme of 2'-5' oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family. J Biol Chem 2001;276:25447-25455.
41. Hartmann K, Artuc M, Baldus SE, et al. Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis. Am J Pathol 2003;163:819-826.
42. Roth KA, Kuan C, Haydar TF, et al. Epistatic and independent functions of caspase-3 and Bcl-X(L) in developmental programmed cell death. Proc Natl Acad Sci U S A 2000;97:466-471.
43. Romani AA, Desenzani S, Morganti MM, Baroni MC, Borghetti AF, Soliani P. The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid. Cancer Chemother Pharmacol 2011;67:557-567.
44. Opferman JT, Iwasaki H, Ong CC, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005;307: 1101-1104.
45. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987;8:138-140.
46. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467-1472.
47. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008;5:621-628.
48. Kerrien S, Aranda B, Breuza L, et al. The IntAct molecular interaction database in 2012. Nucleic Acids Res 2012;40(Database issue):D841-D846.
49. Cline MS, Smoot M, Cerami E, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2007;2:2366-2382.
50. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005;21:3448-3449.